Literature DB >> 11840449

Therapeutic effects of acetylsalicylic acid in giant cell arteritis.

Cornelia M Weyand1, Markus Kaiser, Hongyu Yang, Brian Younge, Jörg J Goronzy.   

Abstract

OBJECTIVE: In giant cell arteritis (GCA), inflammatory lesions typically produce interferon-gamma(IFNgamma)-- and nuclear factor kappaB (NF-kappaB)-dependent monokines. Corticosteroids influence disease activity by repressing NF-kappaB-dependent genes but have only marginal effects on IFNgamma. The current study explored whether acetylsalicylic acid (ASA) had cytokine-repressing activity in GCA and could function as a steroid-sparing agent.
METHODS: Temporal artery-severe combined immunodeficiency (SCID) mouse chimeras were created by engrafting inflamed temporal arteries into SCID mice. Chimeras were treated with ASA, indomethacin, or dexamethasone for 3 weeks. Temporal artery grafts were harvested and cytokine message was semiquantified by polymerase chain reaction-enzyme-linked immunosorbent assay. The ability of dexamethasone and ASA to suppress IFNgamma and interleukin-1beta (IL-1beta) messenger RNA and protein production was also tested in vitro using T cell clones and monocytes derived from patients with GCA. Drug-induced effects on the transcription factors NF-kappaB and activator protein 1 (AP-1) were assessed by electrophoretic mobility shift assays (EMSAs).
RESULTS: At clinically relevant doses, 20-100 mg/kg, ASA was a highly effective inhibitor of cytokine transcription in temporal arteries. While dexamethasone preferentially targeted NF-kappaB-regulated monokines, ASA acted predominantly by suppressing IFNgamma. Indomethacin failed to reduce tissue IFNgamma transcription, which therefore excluded the inhibition of cyclooxygenases as a critical mechanism. IFNgamma production by T cell clones was highly sensitive to ASA-mediated suppression, whereas IL-1beta production by lipopolysaccharide-stimulated monocytes responded primarily to dexamethasone. The combination of ASA and dexamethasone had synergistic effects. EMSAs demonstrated that ASA interfered with the formation of AP-1, whereas dexamethasone suppressed the nuclear translocation of NF-kappaB.
CONCLUSION: The results of this study provide evidence of the complementary action of ASA and corticosteroids in suppressing proinflammatory cytokines in the vascular lesions of GCA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11840449     DOI: 10.1002/art.10071

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  32 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

2.  [Vertebrobasilar ischemia as a complication of temporal arteritis. Results of a prospective, clinical, ultrasonographic study].

Authors:  K Pfadenhauer; M Esser; H Weber; K D Wölfle
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

3.  Clinical trials in giant cell arteritis.

Authors:  Luis R Espinoza
Journal:  Curr Rheumatol Rep       Date:  2005-08       Impact factor: 4.592

Review 4.  [Pathogenesis of medium- and large-vessel vasculitis].

Authors:  C M Weyand; J J Goronzy
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

5.  Giant cell arteritis and cardiovascular disease in older adults.

Authors:  J G Ray; M M Mamdani; W H Geerts
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

Review 6.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 7.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

Review 8.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 9.  Giant cell arteritis: Current treatment and management.

Authors:  Cristina Ponte; Ana Filipa Rodrigues; Lorraine O'Neill; Raashid Ahmed Luqmani
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

10.  Giant Cell Arteritis.

Authors:  Jennifer K. Hall; Laura J. Balcer
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.